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Abstract
Bioethical principles are widely used as a normative framework in areas of human research and
medical care. In recent years there has been increasing formalization of their use in public health
decisions. The "traditional bioethical principles" are applied in this discussion to the important issue
human biomonitoring for environmental exposures. They are: (1) Autonomy – Also known as the
"respect for humans" principle, people understand their own best interests; (2) Beneficence – "do
good" for people; (3) Nonmaleficence – "do no harm"; (4) Justice – fair distribution of benefits and
costs (including risks to health) across stakeholders.
Some of the points made are: (1) There is not a single generic bioethical analysis applicable to the
use of human biomonitoring data, each specific use requires a separate deliberation; (2) Using
unidentified, population-based biomonitoring information for risk assessment or population
surveillance raises fewer bioethical concerns than personally identified biomonitoring information
such as employed in health screening; (3) Companies should proactively apply normative bioethical
principles when considering the disposition of products and by-products in the environment and
humans; (4) There is a need for more engagement by scholars on the bioethical issues raised by the
use of biomarkers of exposure; (5) Though our scientific knowledge of biology will continue to
increase, there will always be a role for methods or frameworks to resolve substantive
disagreements in the meaning of this data that are matters of belief rather than knowledge.
Introduction
The National Research Council's report on Human Bio-
monitoring identified bioethical concerns as one of the
significant challenges in the use of biomarkers of exposure
for both individual and public health decisions [1]. The
same need has been identified by the EU Commission
and the European Center for Ecotoxicology and Toxicol-
ogy of Chemicals [2,3].
Similar concerns, though more emotive, emerged in the
1980's with increased testing for genetic biomarkers [4].
These concerns accelerated with the Human Genome
Project. Facilitated by significant funding for scholars to
examine anticipated ethical, legal and social issues, many
of the important conflicts have been reasonably well
addressed [5].
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Little scholarly attention has been paid to the bioethical
issues associated with biomarkers for environmental
exposure. Most of the literature is directed to the use of
these technologies in the workplace [6,7]. A 1997 publica-
tion included a discussion of ethical issues of biomarkers
related to environmental exposures – including those for
dose [8]. In the NRC publication mentioned above, ethi-
cal issues related to biomonitoring are discussed primarily
in terms of confidentiality, privacy and nondiscrimina-
tion [1]. A more recent article uses bioethical principles to
analyze the decision to communicate personal biomoni-
toring data to those who have been tested [9].
The purpose of this paper is to contribute to a dialogue on
concerns surrounding biomarkers of exposure for indus-
trial chemicals. This will be done by:
￿ First, making a case for the relevance of normative argu-
mentation to these concerns
￿ Secondly, applying bioethical principles to some spe-
cific decisions that are introduced by the use of biomoni-
toring technologies
Can bioethics aid decision-making related to human 
biomarkers of chemical absorption?
Biomonitoring of humans for markers of chemical expo-
sure has burgeoned because of better sensitivity and
decreased cost of the analytical techniques. The most visi-
ble application of this information is the CDC's "National
Exposure Report" [10] which yields valuable insight into
chemicals we absorb from air, food, water and personal
products. It is difficult to overstate the impact that this
information will have on the way we think about and
manage chemicals and health risk [11,12]. The informa-
tion will enable better medical diagnosis and treatment,
more accurate risk assessment, improved product safety,
and better public health planning.
But, in the near term, there are considerable challenges in
the interpretation of biomonitoring data for individuals
and for purposes of public health. An example of these
challenges is the current public conflict about the predic-
tive value of exposure biomonitoring in terms of individ-
ual health risk. Some groups state or strongly imply that
the presence in the body of any level of manmade chemi-
cals is evidence of increased risk of harm [13-15]. A con-
flicting position states that biomonitoring data for
"environmental chemicals" is not meaningful in the
absence of a proven link between a chemical and a dis-
ease. This line of reasoning often concludes that there is
currently no justification to perform these analyses.
What is the crux of wildly differing interpretations of 
biomonitoring data?
The two extreme interpretations of the value of human
biomonitoring described above are not driven by different
scientific analyses of the data. Unfortunately, the actual
biological knowledge that could support or dispute a link
between low concentrations of chemicals and health
effects is not available [16]. Those who make statements
regarding risk in this area are typically expressing personal
beliefs and values – though, often couched in quasi-scien-
tific jargon. Beliefs and values, however sincerely held, are
outside the realm of scientific inquiry [17]. Among these
important areas of dispute are social justice, progress, the
role of innovation and technology, community, rights,
duties and personal freedom.
These disputes are not unfortunate; they are integral to a
pluralistic society. Decisions cannot be made effectively
without recognizing and addressing them. Knowledge of
the natural world (i.e. science) will narrow the range of
reasonable options. But, science does not offer insights or
methodologies to hasten resolution between conflicting
value systems. In fact, the attempt to resolve these debates
with appeals to science alone is often a diversion to avoid
addressing emotionally charged debates on values
[18,19]. Given the large degree of scientific uncertainty in
the interpretation of environmental biomonitoring data,
and confronted with strongly conflicting beliefs and val-
ues, how can we reach effective decisions?
Argumentation
Argumentation (sometimes called "Rhetoric") is a process
to reach decisions through reasoned persuasion rather
than fiat or whim [20-22]. Unlike the scientific method,
which examines the universal and constant laws of nature,
argumentation applies reason to the particular and con-
tingent realm of human affairs. It is a process to discover
workable resolutions, and in its broadest definition,
includes both "normative" and "non-normative" argu-
ments [23]:
￿ "Normative" arguments employ "high-minded" princi-
ples that the participants have agreed to apply. The parties
agree to be open-minded and willing to change their ini-
tial position. Positions (arguments) are supported by facts
and reason. These processes are ambitious and time con-
suming because they ask the participants to set aside com-
peting self-interests and deeply held beliefs.
￿ "Non-normative" processes involve negotiation or bar-
gaining to reach an acceptable resolution. There is no
attempt to agree upon values or principles. These are
adversarial processes dominated by self-interest. Many of
life's daily tasks, especially in commercial transactions, are
accomplished by non-normative rules. These processesEnvironmental Health 2008, 7(Suppl 1):S8 http://www.ehjournal.net/content/7/S1/S8
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appeal to authority, socially sanctioned beliefs, the status
quo and emotion. When necessary, they employ guile,
deception, and the advantage of proprietary information.
These behaviors are legitimate, efficient and sanctioned in
all societies – as long as the parties understand the rules in
play.
Decisions that impact human health
Many societies believe that decision-making in the area of
human health should be guided by normative frame-
works because:
￿ Health is a fundamental "good" that should not be sub-
ject to negotiation – especially involving the weak, vulner-
able and uniformed
￿ Unlike most harm or damages in life, human health can-
not always be reversed, nor adequately compensated
The willingness to accept a normative framework (in this
case, bioethical principles) for making decisions in the
arena of human health is, in itself, unsupported by any
natural or scientific knowledge. It's a value based decision,
and a sine quo non for participation in a process of bioeth-
ical argumentation.
Applying bioethical principles is a normative 
argumentation process
Bioethical principles have been employed with relative
success in many contentious and value-laden health con-
troversies [24,25]. The important role that this approach
has played in developing public policy around the use of
genetic information was mentioned previously. Other
areas of productive application are procreation and the
right to reproduction, protection of human subjects in
research, life support, euthanasia, abortion, stem cell
research, access to health care, and discrimination based
upon disability. None of these disputes is ever wholly
resolved, but bioethical principles, in concert with other
tools such as casuistry (case precedents) have provided a
framework for productive dialogue [26].
What are the "conventional bioethical principles"?
"Conventional bioethical principles," have gained wide
use for evaluating policies, programs or activities that may
entail risk to human health. This is because they "work" in
the real world. The four major ethical principles in bioeth-
ics are viewed as duties that many contemporary philoso-
phers believe to be prima facie. Prima facie duties take
precedence over any other considerations except another
duty. The "big four" are:
￿ "Autonomy," also known as the "respect for humans"
principle, acknowledges the belief that an individual
understands his or her own best interests better than any-
one else
￿ "Beneficence" means to "do good" for people; all stake
holders are to be considered
￿ "Nonmaleficence," sometimes seen as a corollary to
beneficence, means to "do no harm" to people
￿ "Justice" captures the belief that there should be a fair
distribution of the benefits and costs (including risks to
health) of an activity or program
Beauchamp and Walters list four additional bioethical
principles which they refer to as "secondary principles"
[24]. The one that most often comes into ethics discus-
sions is veracity. A normative process cannot proceed in
the face of disingenuous interpretations of scientific
knowledge and other established truths.
￿ "Utility" describes the idea that actions should achieve
the most good for the greatest number of people.
￿ "Fidelity" means that decisions regarding controversies
should demonstrate consistency with other similar cases
￿ "Veracity" holds that decisions or policies should nei-
ther ignore established truths nor try to state beliefs as
such
￿ "Confidentiality" is the idea that an individual's right to
privacy should be protected
How do principles work?
Making decisions guided by these principles is an iterative
dialogue between parties, the more culturally and philo-
sophically diverse the better. The principles are not viewed
as rigid rules or prohibitions, but provide a vocabulary
and useful "warrants" during argumentation. Decisions
require practical compromises that are highly dependent
upon context, precedents, and a well-honed sense of the
"possible" [27].
Different, equally talented groups can come to different
conclusions when faced with identical problems whether
in an Institutional Review Board (IRB) or a public policy
discussion. In fact; the same group can deliver different
answers on different days. This isn't surprising if one rec-
ognizes that difficult decisions do not typically address
"right versus wrong". Difficult decisions invariably result
when the choices involve "right versus right" [28]. Some
important points to make about bioethical argumenta-
tion are:
￿ Bioethical principles offer guidance, but no absolutes.Environmental Health 2008, 7(Suppl 1):S8 http://www.ehjournal.net/content/7/S1/S8
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￿ Principles often conflict; no principle is preeminent.
￿ Bioethical principles are not employed in argumenta-
tion at the exclusion of other equally powerful "tools,"
notably casuistry.
￿ No activity or program is inherently ethical or unethical;
they are judged by balancing benefits and risks to all
stakeholders while guided by principles.
￿ Any form of deception is viewed as inherently unethical
in normative deliberations.
￿ The specific use of biomonitoring data determines the
principles that are most germane; this discussion arbitrar-
ily groups the uses into four areas – human research, pub-
lic health, product stewardship and medical practice.
Discussion
Human research
Research designed to validate or employ biomarkers for
exposure does not create any unique issues. The applica-
tion of bioethical principles to human research is highly
developed and codified in documents such as the "Decla-
ration of Helsinki" [29], the "International Ethical Guide-
lines for Biomedical Research Involving Human Subjects"
[30] and in regulations such as the U. S. "Common Rule"
[31]. Protections such as informed consent, written proto-
cols and publication of all findings are widely practiced
under the purview of IRBs in the U.S. and Regional Ethics
Committees and Institutional Ethics Committees in other
parts of the world [32,33].
The principles have been used to address other considera-
tions in the conduct of research besides direct harm to
participants. Notably, there is increasing interest on the
part of IRB members in the scientific validity of proposed
research. The rationale is simple: if the design of proposed
research does not offer the prospect of yielding objective
and scientifically valid conclusions, there is no justifica-
tion for either the expenditure of resource or subjecting
participants to even de minimis risk. Research protocols
that are fundamentally flawed cannot be justified in the
light of the principles of beneficence and veracity. A recent
review on proposed research using pesticides makes the
point well in terms of accepting research results for rule-
making.
"Any study that is not scientifically valid – for exam-
ple, does not include a sufficient number of subjects to
provide statistically valid answers to the questions
under investigation -must not be considered in stand-
ard setting" [34]
Bioethical principles go further and support the argument
that these decisions should be made before the research is
initiated. Poorly designed studies involving human sub-
jects should not be undertaken.
Another conflict that has arisen with human biomarkers is
the desire of research participants to learn their individual
results. There is no easy answer, and two principles, non-
maleficence and autonomy, seem to give different
answers. A careful balancing of risks and benefits by the
investigators may argue against sharing individual data in
the early stages of investigating a biomarker. This is an
ethically supportable position as long as the research par-
ticipants are informed of the decision to not disclose
before participation. A precedent for this position has
been established in genetic research because of the psy-
chological and financial harm that can ensue from misin-
formation on health risk [35]. Another view of this issue,
described as the "community-based participatory
research" approach emphasizes the "right to know"
(autonomy), and argues that individual data should rou-
tinely be shared with research participants [9]. This posi-
tion is not unreasonable, but the facts, context and
stakeholders in specific cases could support different deci-
sions.
The U.S. Center for Disease Control's National Exposure
Report is a good example of how biomonitoring informa-
tion can be generated and communicated with high scien-
tific and ethical standards [10]. Individual test results are
not given unless the concentration is markedly above
population means. Notification in these rare cases is ethi-
cally justified because an individual may be able to iden-
tify the source of unusual exposure and correct it. The
principle of beneficence argues for disclosure. At the same
time, the CDC is careful to emphasize that mere presence
of the chemical, even at multiple standard deviations
above the group mean does not imply health risk (the
principles of nonmaleficence and veracity are thereby sat-
isfied).
One of the important ethical questions in the area of
human research is why many organizations do not adopt
frameworks to protect human subjects and to ensure that
the research has scientific value. Though this is not legally
required for privately funded research, the failure of
organizations to voluntarily adopt the Common Rule or a
similar standard of behavior raises questions about the
integrity of their research programs. Multiple bioethical
principles support arguments against the conduct of
human research without appropriate protections (e.g.
autonomy, beneficence, utility and veracity) [36].
The area of human research has served as the beachhead
for the application of bioethics to real world societal con-Environmental Health 2008, 7(Suppl 1):S8 http://www.ehjournal.net/content/7/S1/S8
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troversies. Difficult decisions in areas besides research can
also benefit from disciplined argumentation that employs
these processes and principles.
Public health including surveillance
Surveillance activities are designed to detect environmen-
tal conditions that increase the risk of adverse health out-
comes with the purpose of controlling or eliminating
those conditions [37]. Conceptually, surveillance does
not address individual risk, though the same data can be
used to do so (medical screening).
Using biomonitoring data as a surveillance tool is already
contributing to improved public health protections.
Examples are:
￿ monitoring time trends of chemical concentrations in
the population to better target testing
￿ validating the effectiveness of regulation
￿ targeted assessment of populations suspected to be in
environmental "hotspots"
￿ investigating "clusters" of disease that might be related
to an environmental exposure
￿ detecting emerging exposures that were unsuspected
From a bioethical perspective, any reasoned analysis
seems to argue for a very broad application of biomoni-
toring technology for the purposes above. Surveillance,
which by definition, is not engaged in research, should
use only validated biomarkers. Also, because surveillance
looks at group analyses, the thorny issues that accompany
individual results can largely be avoided.
There is a long history of using exposure biomarkers in the
workplace, though its application has been much more
extensive in Europe than in North America. The American
Council of Governmental and Industrial Hygienists has
developed Biological Exposure Indices (BEIs) for approx-
imately 50 chemicals [38]. These guidelines are designed
to be used by industrial hygienists in making decisions
regarding safe levels of exposure to chemical substances in
the workplace. German Biological Tolerance Values (BAT
values) are similar, but derived for medical screening and
diagnosis purposes [39]. There are significant regulatory
and work council constraints in the occupational setting
that do not apply to biomonitoring for environmental
exposure. These formal rules ensure the validity of the
analyses, and protect against breach of confidentiality and
discrimination in employment or other benefits. Absent
these protections and those of the Common Rule, partici-
pants in environmental biomonitoring depend upon the
ethical sophistication and good intentions of the admin-
istrators of these programs.
A significant challenge for these state-of-the-art analyses is
that they must be done competently. This is not easy [40].
The measurements are being done on very low concentra-
tions of analyte, there is little standardization of the meth-
ods and there is no independent process for assuring the
quality of the analyses. Large, experienced labs, such as
the one at the National Center for Environmental Health
have the skills, resources and quality control systems to
optimize the validity of the results. But the measurement
of these biomarkers is done largely by small unaccredited
labs. Issues of sample collection, storage and transport are
also major challenges. It is profoundly unethical to com-
municate data used for human health decisions unless all
efforts have been taken to assure its integrity. Even then
the result should be communicated with accurate descrip-
tions of the test validity.
Another bioethical consideration arises when specific
communities are selected for testing. The rationale may be
very sound, but the risk of stigmatizing an ethnic, geo-
graphical or professional community needs to be dis-
cussed. This will become more salient if and when the low
concentrations of environmental chemicals being
detected to date are linked to increased health risk. Even
then, nonmaleficence does not necessarily take prece-
dence over potential benefits, but this consideration
needs to be balanced against the anticipated benefits.
Regulatory risk assessment is an important element of 
public health practice
Biomonitoring information is currently not employed in
these processes because there is not enough factual knowl-
edge about the linkage between a specific biomarker of
absorption and human disease [41,42]. Exposure biomar-
kers will augment, and in some cases, supplant exposure
estimates for the purpose of risk assessments, but the val-
idation work is yet to be done.
In the near term, biomarkers of exposure can be linked to
established human reference values for environmental
exposure with physiologically based pharmacokinetic
(PBPK) information [43]. This process enabled the devel-
opment of workplace BEIs discussed above. The necessary
PBPK information – which describes the biology of how a
chemical is absorbed, distributed, metabolized and
excreted – exists for no more than 100 chemicals. That
information makes it possible to model the relationship
between a biomonitoring concentration and existing
health-based criteria such as reference doses (RfDs) or tol-
erable daily intakes (TDIs). Calculating the concentration
of a "biomonitoring equivalent" (BE) yields a screening
tool that enables a qualified statement on population risk.Environmental Health 2008, 7(Suppl 1):S8 http://www.ehjournal.net/content/7/S1/S8
Page 6 of 8
(page number not for citation purposes)
The main ethical challenge will be recognize the technical
uncertainties in these derivations, and to not overstate the
meaning of a measurement in terms of either safety or
increased risk for an individual.
Product stewardship
Product stewardship is a public health activity that
requires its own analysis because it is the responsibility of
the private sector. This gives the organizations involved
much greater latitude in terms of strategy and resources as
they do not have to justify their actions to politicians and
the public. At the same time, the responsibility creates sig-
nificant normative ethical expectations that are not clearly
defined.
Product stewardship decisions rely upon assessments of
risk. The area of greatest uncertainty in these is exposure
estimation – a methodology generously described as an
educated guess. The availability of human biomonitoring
technologies creates an opportunity for product stewards
to understand and utilize its capabilities. The techniques
should be employed if they are likely to yield a more accu-
rate assessment of risk to customers and the community.
It is likely that this will not be necessary in most cases. But,
this decision can be made only after a systematic assess-
ment of the potential contribution of exposure biomoni-
toring for each product or emission. All of the bioethical
principles listed above are applicable to these decisions.
Medical practice
The use of population-based biomonitoring information
in risk assessment and other public health applications
raises fewer ethical objections than the use of the same
data when it is personally identified. The latter routinely
leads into the realms of medical screening and medical
diagnosis where well-intentioned efforts can cause great
harm.
Medical diagnosis and treatment occurs in a special rela-
tionship – that of physician and patient. A symptomatic
individual [a patient] initiates that relationship when they
ask for help. The physician is ethically and legally com-
mitted to a fiduciary role in which he or she puts the best
interests of the patient above other considerations. At a
minimum, the practitioner is expected to be adequately
trained, licensed and knowledgeable about the tests and
therapies that he or she employs. This includes under-
standing the scientific rationale of any biomarkers in
order to be able to interpret and act on the information.
Given the current paucity of knowledge about the biolog-
ical significance of environmental chemicals at the tissue
concentrations that have been documented, it is highly
unlikely that a responsible physician will link these doses
to a disease, nor recommend any treatment or preventive
actions. To do so risks harming the patient in multiple
ways – physically, psychologically and financially – with-
out any evidence of likely benefit. The legal, professional,
financial and reputational sanctions for this type of
breach of a physician's duty are severe. While we can read-
ily apply the principles of autonomy, veracity, beneficence
and nonmaleficence to an analysis of this decision, it may
well be the more pedestrian principle of enlightened self-
interest that proves to be most persuasive with medical
practitioners.
The use of biomarkers of environmental exposure to
accomplish medical screening (very different in concept
than either surveillance or diagnosis) certainly strays far-
ther from the "moral sphere" than anything discussed to
this point. Screening is an activity in which an individual
without any symptoms is tested for early signs of a dis-
ease. While some screening tests [and screening programs]
are scientifically and ethically sound, many of these activ-
ities meet neither test. There are many well documented
reasons for this, but, in short, there is a fundamental ina-
bility of most tests to predict future presence or absence of
disease [44,45].
In the case of current biomarkers of environmental expo-
sure, it is difficult to imagine that the "screeners," believe
that they are benefiting individuals by sharing personal
test data. The principle of autonomy supports the "right to
know," but the principles of beneficence, nonmaleficence
and veracity seem to support nondisclosure. One reason is
that it is highly unlikely that an individual gains any ben-
efit in knowing his personal test results as opposed to the
readily available group mean given to the community
(certainly, valuable knowledge). This statement assumes
that, as is the case with the CDC's programs, any notably
high numbers are reported routinely to the participant.
Is there any "actionable" information in personal data
from routine environmental biomonitoring? The answer
to this question provides the kind of factual context
("specification" in the language of Tom Beauchamp) that
allows practical guidance to be drawn out of general
moral principles [46]. And, he adds, don't forget the value
and authority of "paradigmatic cases," i.e. casuistry, which
works hand in glove with bioethical principles. In the case
of harm done to individuals by medical screening there is
a very rich literature [47,48].
Conclusion
It is often said that the ability to measure chemicals in
humans is far outpacing the ability to interpret these data
for public and individual health purposes. Future research
will yield evermore knowledge of the biology that links
exposure to effect, and will reduce the uncertainties. Even
then, we will need a way to resolve substantive disagree-
ments in the meaning of this data that are matters of beliefEnvironmental Health 2008, 7(Suppl 1):S8 http://www.ehjournal.net/content/7/S1/S8
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rather than knowledge. Both now and in the future, a nor-
mative argumentation framework, using bioethical princi-
ples in conjunction with other practical tools such as
casuistry, offers a reasonable approach to improving deci-
sions that involve human health impacts. Not only does
the process surface important disagreements in values, but
when done well, illuminates unsupportable interpreta-
tions of science.
"Engaging in the steps of an ethics analysis makes us
meticulous in our reasoning, requiring us to advocate
interventions on the basis of facts and not merely
belief. Further, an ethics analysis holds us to high
standards, not only for scientific method, but also for
how respectfully we communicate with and involve
constituent communities." [49]
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